{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:44:00Z","timestamp":1789685040685,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014076","name":"Stichting ALS Nederland","doi-asserted-by":"publisher","award":["EVIDENCE"],"award-info":[{"award-number":["EVIDENCE"]}],"id":[{"id":"10.13039\/501100014076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00415-024-12813-3","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T12:22:22Z","timestamp":1734006142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Attrition and discontinuation in amyotrophic lateral sclerosis clinical trials: a meta-analysis"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-5967","authenticated-orcid":false,"given":"Ruben P. A.","family":"van Eijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4871-2567","authenticated-orcid":false,"given":"Floris T.","family":"van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-6740","authenticated-orcid":false,"given":"Jordi W. J.","family":"van Unnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4182-3294","authenticated-orcid":false,"given":"Daphne N.","family":"Weemering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-1892","authenticated-orcid":false,"given":"Georgios","family":"Seitidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-4592","authenticated-orcid":false,"given":"Dimitris","family":"Mavridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-9674","authenticated-orcid":false,"given":"Leonard H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-3725","authenticated-orcid":false,"given":"Stavros","family":"Nikolakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"12813_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1212\/WNL.0b013e3182a823e0","volume":"81","author":"N Atassi","year":"2013","unstructured":"Atassi N, Yerramilli-Rao P, Szymonifka J et al (2013) Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology 81:1350\u20131355","journal-title":"Neurology"},{"key":"12813_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/bmj.332.7547.969","volume":"332","author":"JC Dumville","year":"2006","unstructured":"Dumville JC, Torgerson DJ, Hewitt CE (2006) Reporting attrition in randomised controlled trials. BMJ 332:969\u2013971","journal-title":"BMJ"},{"key":"12813_CR3","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jclinepi.2013.03.019","volume":"66","author":"R Crutzen","year":"2013","unstructured":"Crutzen R, Viechtbauer W, Kotz D, Spigt M (2013) No differential attrition was found in randomized controlled trials published in general medical journals: a meta-analysis. J Clin Epidemiol 66:948\u2013954","journal-title":"J Clin Epidemiol"},{"key":"12813_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/08870446.2014.953526","volume":"30","author":"R Crutzen","year":"2015","unstructured":"Crutzen R, Viechtbauer W, Spigt M, Kotz D (2015) Differential attrition in health behaviour change trials: a systematic review and meta-analysis. Psychol Health 30:122\u2013134","journal-title":"Psychol Health"},{"key":"12813_CR5","unstructured":"Higgins JPT, Cochrane Collaboration (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley-Blackwell, Hoboken, NJ"},{"key":"12813_CR6","volume-title":"Experimental and quasi-experimental designs for generalized causal inference","author":"WR Shadish","year":"2001","unstructured":"Shadish WR, Cook TD, Campbell DT (2001) Experimental and quasi-experimental designs for generalized causal inference. Houghton Mifflin, Boston"},{"key":"12813_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM (2005) External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d Lancet 365:82\u201393","journal-title":"Lancet"},{"key":"12813_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00415-023-12010-8","volume":"271","author":"E Beswick","year":"2024","unstructured":"Beswick E, Johnson M, Newton J et al (2024) Factors impacting trial participation in people with motor neuron disease. J Neurol 271:543\u2013552","journal-title":"J Neurol"},{"key":"12813_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1080\/01616412.2023.2194184","volume":"45","author":"J Sznajder","year":"2023","unstructured":"Sznajder J, Barc K, Kuzma-Kozakiewicz M (2023) Low intensity exercise training in patients with amyotrophic lateral sclerosis - factors influencing eligibility and compliance to the clinical trial. Neurol Res 45:708\u2013716","journal-title":"Neurol Res"},{"key":"12813_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1212\/WNL.0000000000007695","volume":"93","author":"JA Andrews","year":"2019","unstructured":"Andrews JA, Bruijn LI, Shefner JM (2019) ALS drug development guidances and trial guidelines: consensus and opportunities for alignment. Neurology 93:66\u201371","journal-title":"Neurology"},{"key":"12813_CR11","doi-asserted-by":"publisher","first-page":"e087970","DOI":"10.1136\/bmjopen-2024-087970","volume":"14","author":"FT van Loon","year":"2024","unstructured":"van Loon FT, Seitidis G, Mavridis D et al (2024) A living systematic review and comprehensive network meta-analysis of ALS clinical trials: study protocol. BMJ Open 14:e087970","journal-title":"BMJ Open"},{"key":"12813_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3109\/21678421.2016.1148169","volume":"17","author":"JM Shefner","year":"2016","unstructured":"Shefner JM, Wolff AA, Meng L et al (2016) A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 17:426\u2013435","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"12813_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2023.2851","volume":"80","author":"A Genge","year":"2023","unstructured":"Genge A, van den Berg LH, Frick G et al (2023) Efficacy and safety of ravulizumab, a complement C5 inhibitor, in adults with amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol 80:1089\u20131097","journal-title":"JAMA Neurol"},{"key":"12813_CR14","first-page":"1331","volume":"19","author":"RPA van Eijk","year":"2019","unstructured":"van Eijk RPA, Nikolakopoulos S, Roes KCB et al (2019) Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry 19:1331\u20131337","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12813_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","volume":"21","author":"TH Barker","year":"2021","unstructured":"Barker TH, Migliavaca CB, Stein C et al (2021) Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol 21:189","journal-title":"BMC Med Res Methodol"},{"key":"12813_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.178","volume":"3","author":"L Lin","year":"2020","unstructured":"Lin L, Xu C (2020) Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives. Health Sci Rep 3:e178","journal-title":"Health Sci Rep"},{"key":"12813_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/sim.4780100410","volume":"10","author":"DB Rubin","year":"1991","unstructured":"Rubin DB, Schenker N (1991) Multiple imputation in health-care databases: an overview and some applications. Stat Med 10:585\u2013598","journal-title":"Stat Med"},{"key":"12813_CR18","doi-asserted-by":"publisher","DOI":"10.1201\/9780429492259","volume-title":"Flexible imputation of missing data","author":"SV Buuren","year":"2018","unstructured":"Buuren SV (2018) Flexible imputation of missing data, 2nd edn. CRC Press, Taylor & Francis Group, Boca Raton, FL","edition":"2"},{"key":"12813_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1\u201348","journal-title":"J Stat Softw"},{"key":"12813_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","volume":"21","author":"JS Mora","year":"2020","unstructured":"Mora JS, Genge A, Chio A et al (2020) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 21:5\u201314","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"12813_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"HJ Westeneng","year":"2018","unstructured":"Westeneng HJ, Debray TPA, Visser AE et al (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17:423\u2013433","journal-title":"Lancet Neurol"},{"key":"12813_CR22","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1212\/WNL.0000000000007022","volume":"92","author":"RPA van Eijk","year":"2019","unstructured":"van Eijk RPA, Westeneng HJ, Nikolakopoulos S et al (2019) Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 92:e451\u2013e460","journal-title":"Neurology"},{"key":"12813_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","volume":"21","author":"M Geissbuhler","year":"2021","unstructured":"Geissbuhler M, Hincapie CA, Aghlmandi S, Zwahlen M, Juni P, da Costa BR (2021) Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study. BMC Med Res Methodol 21:123","journal-title":"BMC Med Res Methodol"},{"key":"12813_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209503","volume":"103","author":"DN Weemering","year":"2024","unstructured":"Weemering DN, Beelen A, Kliest T, van Leeuwen LAG, van den Berg LH, van Eijk RPA (2024) Trial participation in neurodegenerative diseases: barriers and facilitators: a systematic review and meta-analysis. Neurology 103:e209503","journal-title":"Neurology"},{"key":"12813_CR25","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1212\/01.wnl.0000336652.05779.ea","volume":"71","author":"J Karlawish","year":"2008","unstructured":"Karlawish J, Cary MS, Rubright J, Tenhave T (2008) How redesigning AD clinical trials might increase study partners\u2019 willingness to participate. Neurology 71:1883\u20131888","journal-title":"Neurology"},{"key":"12813_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2018.1556698","volume":"20","author":"RS Bedlack","year":"2019","unstructured":"Bedlack RS, Wicks P, Vaughan T et al (2019) Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotroph Lateral Scler Frontotemporal Degener 20:1\u20139","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"12813_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","volume":"18","author":"DM Finkelstein","year":"1999","unstructured":"Finkelstein DM, Schoenfeld DA (1999) Combining mortality and longitudinal measures in clinical trials. Stat Med 18:1341\u20131354","journal-title":"Stat Med"},{"key":"12813_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","volume":"33","author":"SJ Pocock","year":"2012","unstructured":"Pocock SJ, Ariti CA, Collier TJ, Wang D (2012) The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 33:176\u2013182","journal-title":"Eur Heart J"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12813-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12813-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12813-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:58:34Z","timestamp":1738173514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12813-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["12813"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12813-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients provided their consent during trial participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"40"}}